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Abstract
Arecoline, a drug obtained from the Areca Catechu L., induced a dose-dependent antinociception (0.3–1 mg kg−1 i.p.) which
was prevented by the muscarinic antagonists pirenzepine (0.1 g per mouse i.c.v.) and S-(− )-ET-126 (0.01 g per mouse i.c.v.).
A dose-dependent inhibition of the antinociception induced by arecoline was observed after inactivation of the M1 gene by an
antisense oligodeoxyribonucleotide (aODN). This effect was detected 24 h after the last i.c.v. injection of aODN. These results
indicate that arecoline antinociception is mediated by the activation of central M1 muscarinic receptors. © 2001 E´ditions
scientifiques et me´dicales Elsevier SAS
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1. Introduction
Arecoline is a component, together with arecaine,
guvacine and guvacholine, in the areca walnut that is
the seed of Areca Catechu L. endowed with antinoci-
ceptive properties through a cholinergic mechanism
[1,2].
M1 selective agonists McN-A-343 and AF-102B are
able to produce a significant enhancement of the pain
threshold antagonised by the M1 antagonists dicy-
clomine and pirenzepine [3]. Since it has been demon-
strated that muscarinic analgesia in mice and rats is
mediated by post-synaptic M1 receptors, we thought it
worthwhile to identify the muscarinic receptor subtype
responsible for arecoline antinociception.
2. Experimental
2.1. Animals
Male Swiss albino mice (23–30 g) from Morini (San
Polo d’Enza, Italy) were used. All experiments were
carried out according to the guidelines of the European
Community Council for experimental animal care.
2.2. Antisense oligonucleotides
The 18-mer phosphorothioate antisense ODN
(aODN) 5-CAC TGA GGT GTT CAT TGC-3 com-
plementary to the residues 112–129 of the published
mouse M1 cDNA sequence [4] and the 18-mer phospho-
rothioate fully degenerate ODN (dODN) 5-
NNN NNN NNN NNN NNN NNN-3 (where N is G,
C, A, or T) were vehiculated intracellularly by an
artificial cationic lipid (DOTAP 13 M). The i.c.v.
administration of ODNs was performed under ether
anaesthesia according to the method described by Ha-
ley and McCormick [5].
2.3. Hot-plate test
The method adopted was described by O’Callaghan
and Holtzman [6].
2.4. Statistical analysis
All experimental results are given as the means
SEM. An analysis of variance (ANOVA), followed by
Fisher’s protected least significant difference (PLSD)
procedure for post-hoc comparison, was used to verify
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Fig. 1. Effect of pirenzepine and S-(− )-ET-126 on arecoline-induced
antinociception in mouse hot-plate test. Pirenzepine and S-(− )-ET-
126 were administered 10 min before arecoline. Nociceptive response
was recorded 15 min after arecoline (1 mg kg−1 i.p.) injection.
Number of mice ranged between 8 and 18. Vertical lines show SEM.
*P0.01 vs saline-treated mice. °P0.01 vs arecoline-treated mice.
3. Results and discussion
The selective M1 antagonists pirenzepine (0.03–0.1
g per mouse i.c.v.), and S-(− )-ET-126 (0.001–0.01 g
per mouse i.c.v.) prevented arecoline (1 mg kg−1 i.p.)
antinociception (Fig. 1). Pirenzepine and S-(− )-ET-
126, at the same concentration, did not prevent the
analgesia induced by morphine (7 mg kg−1 i.p.) and
amitriptyline (15 mg kg−1 i.p.) (data not shown).
aODN, at the dose of 0.3 nmol per i.c.v. injection, did
not significantly affect arecoline (Fig. 2, panel A) anal-
gesia whereas at the dose of 1.0 and 2.0 nmol per i.c.v.
injection, aODN dose-dependently prevented arecoline
(Fig. 2, panels B and C) antinociception. The regression
line which illustrates the dose-dependent reduction of
arecoline antinociception produced by increasing con-
centrations of aODN is shown in Fig. 2, panel D. The
prevention by the i.c.v. injection of the aODN also
indicates that the antinociception induced by arecoline
is centrally mediated.
The aODN pretreatment (2.0 nmol per i.c.v. injec-
tion) did not reduce the pain threshold in mice showing
lack of any hyperalgesic effect (Fig. 2), excluding the
the significance of differences between two means. Data
were analysed with the StatView software for the Mac-
intosh (1992).
Fig. 2. Prevention of arecoline (1 mg kg−1 i.p.)-induced antinociception by pretreatment with an antisense ODN (aODN) to M1 gene in the mouse
hot-plate test (panels A–C) and effect of increasing concentrations of aODN to M1 gene on arecoline (1 mg kg
−1 i.p.)-induced antinociception
in the same test (panel D). Mice were i.c.v. injected with vehicle, aODN or degenerated ODN (dODN) at the dose of 0.3 (panel A), 1.0 (panel
B) and 2.0 nmol (panel C) per single i.c.v. injection on days 1, 4 and 7. The hot-plate test was performed 24 h after the last i.c.v. injection. The
evaluation of the analgesic effect was carried out 15 min after arecoline administration. Vertical lines give SEM. Each point represents the mean
of 10–14 mice. *P0.01 in comparison with dODN+arecoline-treated mice.
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possibility that the prevention of arecoline antinocicep-
tion is due to a hyperalgesic effect of the treatment
used.
In summary, our results have shown that arecoline is
able to produce antinociception in mice by activating
M1 muscarinic receptor subtype.
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